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A reduced form of the alpha-lipoic acid, dihydro-alpha-lipoic acid (DHLA) is a potent, naturally 
occurring antioxidant which can be consumed as food constituent or as supplement at doses up to 
600 mg/day. DHLA has inhibitory effect on coagulation as it can reduce concentrations of some 
coagulation factors. In this study, a direct interaction between DHLA and fibrinogen, the main 
protein in coagulation, is described. Binding constant for DHLA/fibrinogen complex is of 
moderate strength (10
4
) and interaction probably occurs in D regions of fibrinogen, as shown by 
docking simulations. Fibrinogen stability remains the same with only marginal structural changes 
in its secondary structure favouring more ordered molecular organisation upon DHLA binding. 
Fibrinogen with bound DHLA forms fibrin with thicker fibers, as measured by coagulation assay 
and is protected from oxidation to certain extent.  Obtained results support beneficial effects of 
DHLA on fibrinogen and consequently on coagulation process, suggesting that DHLA 
supplementation may be indicated for persons with an increased risk of developing thrombotic 
complications, particularly those whose fibrin is characterised by increased oxidative 
modification and formation of thinner and less porous fibers. Also, DHLA in complex with 
fibrinogen can be located at site of injury where it may exert antioxidant effects.  
 

















Fibrinogen is one of the major plasma proteins than circulates in the concentration range from 
4.4 to 10.3 μM (1.5-3.5 g/L) in healthy individuals. This is a large fibrillar glyco-protein with 
molecular mass of 340 kDa. Fibrinogen is a homodimer with (AαBβγ)2 structure [1]. This 
protein is involved in hemostasis, both primary and secondary. Primary haemostasis involves 
aggregation of blood platelets as fibrinogen binds to the platelet membrane IIb/IIIa glycoprotein 
and secondary involves transformation to fibrin and subsequent formation of a fibrin clot [2]. 
Fibrinogen interacts with many molecules that alter its structure and function including proteins, 
ions and small molecules [3]. Also, certain pathologies are characterised by chemically modified 
fibrinogen, which behaves differently than the native protein [4,5]. One of these chemical 
modifications is oxidation and fibrinogen is the most oxidation-susceptible plasma protein [6]. 
Oxidised fibrinogen usually acquires thrombogenic characteristics, such as formation of fibrin 
clot with thinner fibrils and reduced porosity [7–9]. Even if the structure of the oxidised fibrin 
clot is not altered, its porosity may be reduced since protein oxidation creates more hydrophobic 
environment [10]. For this reason, it is relevant to investigate possible interactions of fibrinogen 
with small molecules that are potent antioxidants and to reveal their capacity to protect this 
protein from oxidation and affect the formation of fibrin clot.  
Alpha-lipoic acid (ALA) is a naturally occurring compound that mammalian cells synthesise by 
the action of mitochondrial lipoic acid synthase. It is also commonly found in nutrients such as 
vegetables and meat. ALA and its reduced form dihydro-alpha-lipoic acid (DHLA) have many 
biological effects and act as antioxidants, metal chelators, reducing agents of the oxidised forms 
of other antioxidants (such as vitamins C and E), they improve endothelial dysfunction and 












and doses of 600 mg/day can be used. Bioavailability of the orally administrated ALA in 
aqueous solution can be up to 40 % and food intake reduces it. It is recommended to consume 
the supplement at least 30 min before the meal [12]. Beneficial effects of ALA supplementation 
in patients with diabetes were reported [13,14] and they include reduction of glucose and ROS 
levels, prevention of β cell destruction, enhancement of glucose uptake and slowing down the 
development of diabetic complications. On the other hand, as reported in another study, 
supplementation of 600 mg/day of ALA to older patients with diabetes mellitus type 2 failed to 
exhibit beneficial effects regarding reduction of inflammation, oxidative stress and receptors for 
the advanced glycation end products [15]. The authors of that study suggested testing of  higher 
doses of ALA.  
ALA was shown to modify the coagulation process in several ways. It inhibits activation of 
platelets [13], prolongs the coagulation time affecting an intrinsic coagulation pathway [16] and 
reduces the concentration of some coagulation factors such as fibrinogen, factor VII and von 
Willebrand factor [17].  
The aim of this study was to investigate whether ALA can interact directly with fibrinogen and if 
this binding can modify formation of fibrin clot and protect fibrinogen from harmful oxidation.  
  
2. MATERIALS AND METHODS 
 
2.1 Materials 
All chemicals used were of the analytical grade. Fibrinogen was purchased from Sigma and 
further purified as already reported [18]. A stock solution (5 mM) of DHLA was prepared by 












complete clarification of the solution [19]. This solution of DHLA was used for all subsequent 
experiments, which were performed applying optimised ratios of reactants for each method. 
 
2.2 Investigation of the binding of DHLA to fibrinogen and determination of the binding constant 
The interaction between DHLA and fibrinogen and determination of the binding constant was 
examined by measuring the reduction of the intrinsic fluorescence of fibrinogen (20 nM) in the 
presence of an increasing concentrations of DHLA (0-20 μM, final concentrations), at room 
temperature. The spectra were recorded using RF-6000 spectrofluorometer (Shimadzu, Japan). 
The excitation wavelength was 280 nm and the emission spectra were recorded in the range from 
290 to 450 nm, with slits width of 5 nm. The obtained spectrum for DHA/fibrinogen complex for 
each DHLA concentration was corrected for the background signal originating from DHLA 
itself. Differences in the obtained fluorescence intensities due to the inner-filter effect were 
corrected using the equation: 
 Fc = F0 x 10
(Aex+Aem)/2 
(1) 
where F0 is the measured fluorescence, Fc is the corrected fluorescence, Aex and Aem are 
absorbances at the excitation (280 nm) and the emission (345 nm) peaks.  
In order to determine the type of quenching, Stern-Volmer (SV) plot was drawn using the 
following equation [20]: 
               
𝐹0
𝐹
= 1 + 𝑘𝑞𝜏𝑜[𝑄] = 1 + 𝐾𝑆𝑉[𝑄]         (2) 
Where F0 and F are protein fluorescence intensities at 345 nm in the absence and in the presence 
of DHLA, kq is the bimolecular quenching rate constant, τo is the average lifetime of the 
biomolecule without quencher (10
-8
 s), [Q] is the total concentration of the quencher (DHLA) 












The binding constant, Ka, between fibrinogen and DHLA was calculated using Stern-Volmer 
equation:  








+ 𝑛𝑙𝑜𝑔𝐾𝑎            (3) 
Where F0 and F are emission signals of the fibrinogen in the absence and in the presence of 
DHLA, [L] and [P] are total concentrations of ligand (DHLA) and protein (fibrinogen).  
 
2.3 UV-VIS analysis of DHLA binding to fibrinogen 
UV-VIS analysis of DHLA binding to fibrinogen was performed using Ultrospec 2000 
spectrophotometer (Pharmacia Biotech, Sweden) in the wavelength range from 300 to 425 nm at 
room temperature. Spectra were recorded for DHLA alone (50 μM) and mixtures of fibrinogen 
and DHLA containing 5 or 10 μM fibrinogen and 50 μM DHLA. In order to detect any changes 
in DHLA spectra as a consequence of fibrinogen binding, the spectra obtained for mixtures were 
corrected for the spectra originating from fibrinogen alone.  
 
2.4 Determination of the thermal stability of the DHLA/fibrinogen complex 
The influence of DHLA binding on the thermal stability of fibrinogen was determined using 
FluoroMax®-4 spectrofluorometer (Horiba Scientific, Japan) with Peltier element. Since 
denaturation of fibrinogen is followed by a red shift of its emission spectrum, the ratio of 
fluorescence intensities at 354 and 334 nm was used to investigate its thermal stability. Thermal 
stability of fibrinogen alone (20 nM) or in the presence of DHLA (20 μM) was studied in the 
temperature range from 37 to 81 °C. The rate of the temperature increase was 2 °C/min and the 
equilibration time was set to 1 min. The results are presented as sigmoidal function with the 













2.5 Fourier-transform infrared spectroscopy (FTIR) analysis of the DHLA/fibrinogen complex 
The samples, 6 μM fibrinogen alone or in the presence of 60 or 600 μM (in a total volume of 
50μL) were placed on the ZnSe windows (32 x 2mm, Thermo, Madison, USA) and dried under 
the stream of nitrogen. FTIR measurements were performed using the IRAffinity-1 FTIR 
spectrophotometer (Schimadzu, Japan). The measurements were acquired in a transmission mode 
(100 scans per sample), while the resolution was 4 cm
-1
. Prior to spectral analyses, the spectra 
were preprocessed using Spectragryph software (Menges, 2018). The preprocessing (i.e. 
smoothing and baseline corrections) was done according to the described procedure [21]. 
Deconvolution of the amide I peak was performed using Origine Pro 8.6 software (OrigineLab, 
USA).   
 
2.6 Determination of the effect of DHLA binding on fibrinogen coagulation 
Fibrinogen coagulation assay was performed with fibrinogen at the final concentration of 0.34 
μM, alone or in the presence of DHLA at final concentrations of 0.34 μM or 0.68 μM. Reaction 
mixtures also contained CaCl2 at the final concentration of 2.2 mM and human thrombin, 1 
IU/mL. Coagulation assay was carried out at room temperature in a microtiter plate. Immediately 
after the addition of thrombin, the microplate was placed in Victor
3
V multilabel reader 
(PerkinElmer, USA) and the rise in the absorbance at 350 nm was continually followed for 8 
min. The absorbances of reaction mixtures without fibrinogen were also recorded and used to 
correct the corresponding results obtained in the presence of fibrinogen. The results were 













2.7 Docking analysis of DHLA binding to fibrinogen 
Human fibrinogen crystal structure (PDB Code: 3GHG DOI:10.2210/pdb3GHG/pdb) was 
retrieved from the RCSB protein data bank (https://www.rcsb.org/ accessed Oct. 2019). The 
structure was prepared using Schrodinger Maestro Protein preparation module (Schrödinger 
Release 2018-4: Maestro, Schrödinger, LLC, New York, NY, 2018.). Ligand 2D structure was 
drawn in ChemDraw software (PerkinElmer Informatics, 2015). 2D structure was imported into 
Schrodinger Maestro software and converted to a 3D model with the LigPrep module.  
Prepared protein and ligand were the starting point for Induced Fit Docking protocol [23,24]. 
Potential binding sites were determined using Maestro Sitemap [25] module and standard 
Induced Fit Docking protocol was used to produce up to 20 protein-ligand complexes. The 
obtained complexes were evaluated and the best docking orientation was selected based on the 
number of protein-ligand interactions and the docking score. Results were visualised using 
Schrodinger Maestro software.  
 
2.8 Investigation of the protective potential of DHLA against oxidation of fibrinogen by AAPH 
Reduction of fibrinogen intrinsic fluorescence as a result of 2,2′-azobis(2-amidinopropane) 
dihydrochloride (AAPH)-induced free radical oxidation was used to determine the potential of 
DHLA to protect fibrinogen from oxidation. The same instrument used in section 2.2 was 
applied for this procedure. The analysis was performed at room temperature. To fibrinogen alone 
(100 nM) or in the presence of DHLA (100 or 200 nM), AAPH was added at a final 
concentration of 5 mM. Immediately after AAPH addition, samples were placed in the 
spectrofluorometer and the fluorescence measured at 345 nm (5 nm slits width, 280 nm 












The protective effect (PE), expressed in arbitrary units (a.u.) of DHLA on fibrinogen oxidation 
was quantified using the following equation: 
             PE (a.u.) = AUCFng+DHLA – AUCFng               (4) 
where AUCFng+DHLA is the area under the curve obtained for the oxidation of the 
DHLA/fibrinogen complex, while AUCFng is the area under the curve for the oxidation of free 
fibrinogen. 
 
2.9 Determination of the reducing power of the DHLA/fibrinogen complex 
The reducing power (antioxidative activity) of fibrinogen (7.5 μM), DHLA (7.5 and 15 μM), and 
DHLA/fibrinogen complexes was measured similarly to the published procedure [26]. To 40 μL 
of the sample solution, 100 μL of 0.2 M phosphate buffer (pH 6.6) and 100 μL of 1% potassium 
hexacyanoferrate(III) were added and incubated at 50 °C for 20 min. After incubation, 20% 
trichloroacetic acid was added and the reaction mixture centrifuged at 10000 × g for 8 min. The 
supernatant (100 μL) was mixed with 100 μL of deionised water and 12 μL of 1% 
iron(III)chloride, incubated at room temperature for 2 h and the absorbance measured at 670 nm. 
The masking effect of the protein on the activity of DHLA was calculated using the following 
equation: 
            100% - (100% × AFng+DHLA /ADHLA)             (5) 
where ADHLA and AFng+DHLA are the measured absorbances of DHLA at 670 nm in the absence 
and in the presence of fibrinogen.      













DHLA binds to and reduces the intrinsic fluorescence of fibrinogen upon its excitation at 280 nm 
in a concentration-dependent manner, Figure 1A. The SV quenching constant was calculated to 




, Figure 1B and, from this value, the bimolecular quenching rate constant was 






. This last constant is two orders of magnitude higher than the 






) which suggests that static quenching of fibrinogen 
fluorescence occurs in the presence of DHLA [26]. The binding constant for the 
DHLA/fibrinogen complex was calculated to be 1.01 ± 0.15 x 10
4
, Figure 1C. There was no shift 
in the maximum of the emission spectra due to DHLA binding, implicating that amino acids Tyr 
and Trp in fibrinogen remain in the same or very similar environment in the native protein and 
DHLA/fibrinogen complex.  
Another evidence that the formation of DHLA/fibrinogen complex occurs was acquired from the 
UV-VIS spectral analysis. The absorption maximum of DHLA was at 340 nm. In the presence of 
fibrinogen, there was no change in the intensity of absorbance of DHLA, but a blue shift of the 
maximum occurred. This shift was as large as 22 nm in the presence of 10 μM fibrinogen, Figure 
2. 
The analysis of thermal denaturation revealed that binding of DHLA to fibrinogen doesn’t affect 
protein stability. Fibrinogen alone and DHLA/fibrinogen complex, Figure 3, both had the same 
melting temperature of 53 °C which corresponds to the melting point of the fibrinogen D region 
[27]. These results confirmed spectrofluorometric data, i. e. that there is no significant structural 
alteration of protein upon DHLA binding. To investigate whether any change in the secondary 
structure of fibrinogen occurs upon its interaction with DHLA, FTIR analysis was performed. 
Again, no significant change was detected, Figure 4, even in the presence of high concentration 












expense of reduction of random structures (for 3 %) and turns (for 4 %) was seen, suggesting a 
small contribution of DHLA to the structural order of fibrinogen.   
To investigate possible functional consequences of the interaction between fibrinogen and 
DHLA, two sets of experiments were performed, a coagulation assay (i.e. fibrin formation) and 
an assay to test antioxidative protection of fibrinogen by DHLA. Both experiments were carried 
out at molar ratios of DHLA and fibrinogen which can be obtained under physiological 
conditions. In the coagulation assay, when the molar ratio DHLA:fibrinogen was 2, an increase 
in the maximal absorbance at 350 nm was recorded, without affecting the coagulation time and 
speed, Figure 5. Since this result indicates that thicker fibrin fibers form in the presence of 
DHLA [28], we hypothesised that DHLA may bind to fibrinogen in protein regions involved in 
fibrin formation. 
In order to verify this hypothesis, the Schrodinger Maestro Sitemap module was used to identify 
possible binding sites for docking simulations. Sitemap suggested two most probable binding 
sites and the results of the Induced Fit Docking simulation are presented in Figure 6. The key 
interaction for complex formation is hydrogen bonding between fibrinogen and ALA/DHLA 
carboxyl group, while DHLA can form additional hydrogen bond via a thiol group. In the case of 
the binding site 1, interacting amino acids are Asp 364, Arg 375, Lys 356 and His 340. Similar 
interactions occur at the binding site 2, involving Trp 385, Arg 406 and Asp 432. The 
significance of both binding sites is that they are located in terminal D domains of the fibrinogen 
molecule which are directly involved in the initial association of fibrin fibrils and the latter 
lateral association of growing fibrils [29]. Thus, the proposed model supports our hypothesis and 












As predicted by docking analysis, DHLA needs to be in certain conformation(s) in order to bind 
to fibrinogen at binding sites 1 and 2, and such structural change(s) may be the reason for the 
detection of a blue shift of DHLA in UV-VIS spectral analysis in the presence of fibrinogen. 
This hypothesis, however, needs further experimental confirmation. 
Thicker fibers usually give rise to a fibrin clot with greater porosity, which may be beneficial in 
pathologies accompanied by thrombotic complications, as this implies that the clot can be more 
easily penetrated and lysed by plasmin [30]. This is, however, not always straightforward as in 
some conditions thrombotic fibrin with thicker, but also more rigid fibers forms [31]. One should 
keep in mind that the coagulation assay in our study was performed with the isolated fibrinogen 
and further in vivo investigations using entire blood samples from patients with or at high risk of 
developing thrombotic complications is needed. It must be considered that many factors 
determine the final structure of fibrin clot, such as the concentration of fibrinogen, its structural 
modification, interaction with other proteins, ionic strength of the medium, activity of thrombin 
etc [3,32]. Also, fibrin susceptibility to lysis by plasmin depends on other determinants besides 
fibrin structure and its porosity, such as the protein mass fraction of the clot, the extent of cross-
linking and the presence of some pathology-associated components in plasma, including 
immunoglobulins and cellular microvesicles [33–36].  
Fibrin formation and its structure were shown to be altered in many pathologies characterised by 
thrombotic complications [37–39].  The formation of thrombotic fibrin clot may result as a 
consequence of the oxidation of fibrinogen [10]. This chemical modification is detrimental for its 
function. One possible way to protect fibrinogen from oxidation may be via its interaction with a 
small ligand with potent antioxidant activity. DHLA is one such ligand [40] and in this study we 












stability, and exerting a beneficial effect on its coagulation properties at the same time. Free 
radical oxidation assay using AAPH as an oxidising agent enabled verification of the protective 
role of DHLA against oxidation of fibrinogen, Figure 7A. Surface areas under the curves 
defining progress of fibrinogen oxidation in the absence and in the presence of DHLA served as 
a measure of protein modification. DHLA was able to reduce fibrinogen oxidation by 23 % when 
the molar ratio DHLA:fibrinogen was 2.  
In the last experiment, a reducing activity of the DHLA/fibrinogen complex was investigated 
using hexacyanoferrate (III)/Fe
3+
 assay, Figure 7B. A reducing power of DHLA and fibrinogen 
alone was greater than that of the DHLA/fibrinogen complexes. This finding can be explained by 
the masking effect, which is a well-known consequence of the protein-ligand complex formation 
[41]. A masking effect on the reducing activity in the case of DHLA/fibrinogen complexes was 
calculated to be 31 % and 37 % for the molar ratios of DHLA:fibrinogen 1 and 2, respectively. 
Although masking effect was present, this may not necessarily be a definitive negative 
consequence of the DHLA/fibrinogen interaction, as DHLA may be released from fibrinogen 
during fibrin formation and/or lysis by plasmin. In either case, a released DHLA could exert 
antioxidative effect at the site of injury.     
   
4. CONCLUSION 
Fibrinogen can bind DHLA without significant effect on its structure and stability. The binding 
constant is of the moderate strength and the interaction most probably occurs in D regions of 
fibrinogen. Under conditions which correspond to the possible physiological ratio of the protein 
and the ligand, DHLA can protect fibrinogen from oxidation and stimulate formation of thicker 












consequently on the coagulation process, suggesting that DHLA supplementation may be 
indicated for persons with an increased risk of developing thrombotic complications, particularly 
those whose fibrin is characterised by an increased oxidative modification and formation of 
thinner and less porous fibers.   
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Figure 1. Spectrofluorometric determination of the binding constant between fibrinogen and 
DHLA: A. Reduction in the fluorescence emission intensity of fibrinogen upon DHLA binding 
(fibrinogen concentration was 20 nM and the concentration of DHLA varied in the range 2 - 20 
μM). B. Stern-Volmer (SV) plot for the DHLA/fibrinogen interaction, the slope of the plot is SV 
quenching constant (R
2
 = 0.989). C. Double log plot used for calculation of a binding constant 
between DHLA and fibrinogen (R
2
 = 0.992).   
Figure 2. UV-VIS spectra of DHLA alone (black line), and in the presence of 5 μM (red line) 
and 10 μM fibrinogen (blue line).  
Figure 3. Melting curves for fibrinogen alone (black line), and DHLA/fibrinogen complex (red 
line). Tm is the melting point. 
Figure 4. Investigation of the secondary structure of fibrinogen upon DHLA binding by FTIR. 
Deconvoluted FTIR spectra of the amide I signal were obtained for:  A. Fibrinogen (6 μM); B. 
DHLA/fibrinogen complex (6 μM and 60 μM, respectively) and C. DHLA/fibrinogen complex 
(6 μM and 600 μM). Individual secondary structures are represented by color-coding.  
Figure 5. The effect of DHLA bound to fibrinogen on fibrin formation. A coagulation curve for: 
fibrinogen alone (0.34 μM, black squares) and in the presence of DHLA (0.34 μM, red triangles 
or 0.68 μM, blue circles).   
Figure 6. Docking simulation results. A. Partial 3D model of human fibrinogen (PDB: 3GHG) 












Trp residues are displayed as CPK model and secondary structure is depicted by ribbons. B. 
DHLA interaction at two binding sites 1 (left) and 2 (right). Both 3D model and 2D interaction 
schemes are given. Magenta lines represent hydrogen bonds. Only amino acid residues in close 
contact with the ligand are shown for clarity. 
Figure 7. Investigation of antioxidant and reducing power of DHLA. A. Oxidation of fibrinogen 
(100 nM) by AAPH in the absence (black line) and in the presence of DHLA (100 nM, red line 
or 200 nM, blue line); a reduction in protein fluorescence at 345 nm upon AAPH addition was 
recorded for 15 min. B. Determination of the reducing power of fibrinogen (7.5 μM), DHLA (7.5 
and 15 μM) and their complexes by using potassium hexacyanoferrate (III)/Fe
3+
 assay; the 
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